| abstract |
The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R a which is/are selected, independently of each other, from halogen, CN, NO 2 , CO 2 R 4 , COR 5 , C 1 —C 4 -alkyl and C 1 —C 4 -haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R b , which is/are selected from halogen, NO 2 , CN, CO 2 R 4 , COR 5 , C 1 —C 6 -alkyl, C 2 —C 6 -alkenyl, C 2 —C 6 -alkynyl, C 3 —C 6 -cycloalkyl, C 3 —C 6 -cycloalkyl-C 1 —C 4 -alkyl and C 1 —C 4 -haloalkyl, with it also being possible for two radicals R b which are bonded to adjacent C atoms of Ar to be together C 3 —C 4 -alkylene; R 1 is hydrogen, C 1 —C 4 -alkyl, C 1 —C 4 -haloalkyl, C 3 —C 6 -cycloalkyl, C 3 —C 6 -cycloalkyl-C 1 —C 4 -alkyl, C 1 —C 4 -hydroxyalkyl, C 1 —C 4 -alkoxy-C 1 —C 4 -alkyl, C 3 —C 4 -alkenyl or C 3 —C 4 -alkynyl; with the radicals n, R 1 , R 2 , R 3 , R 4 and R 5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D 3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function. |